ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of

ADDEX THERAPEUTICS LTD

INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Balance

as of September 30, 2024, and December 31,

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

for the three-month and nine-month periods

ended September 30, 2024 and 2023

The comparative information has been re-presented due to discontinued operations that have been reclassed to the financial

line called "Net profit or loss from discontinued operations" (note 21). In the other sections of these unaudited interim

condensed consolidated financial statements an asterisk will indicate where comparative information has been re-presented.

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Comprehensive Income or Loss

for the three-month and nine-month periods

ended September 30, 2024 and 2023

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the nine-month periods ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the three-month period ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the three-month period ended September 30,

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

for the nine-month periods ended September 30,

During the nine-month period ended September 30,

2024, the Group reported a net gain of CHF 13.96 million of which CHF 8.87 million relates to non-cash items including CHF 9.43 million

for the fair value of its 20 % participation in Neurosterix US Holdings LLC and CHF 0.2 million for the fair value of the service agreement

provided at zero cost partially offset by the accelerated vesting of equity incentive units of employees transferred to Neurosterix Pharma

S rl amounting to CHF 1.2 million (note 21). During the same period, the share of the net loss of associates amounted to CHF 1.4

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Notes to the Interim Condensed Consolidated

Financial Statements

Addex Therapeutics Unaudited Interim

Condensed Consolidated Financial Statements Notes

for the nine-month period ended September 30,

(Amounts in Swiss francs)

1. General information

Addex Therapeutics Ltd (the "Company")

and its subsidiaries (together, the "Group") are a clinical stage biopharmaceutical company focused on developing a portfolio

of novel small molecule allosteric modulators for neurological disorders.

The Company is a Swiss stockholding corporation

domiciled c/o Addex Pharma SA, Chemin des Aulx 12, CH 1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma

SA, Addex Pharmaceuticals France SAS, Neurosterix SA and Addex Pharmaceuticals Inc. Addex Therapeutics also owns a 20% equity interest

in Neurosterix US Holdings LLC, USA. Neurosterix US Holdings LLC fully owns directly Neurosterix Swiss Holdings AG, Switzerland and indirectly

Neurosterix Pharma S rl whose principal place of business is Chemin des Mines 9, CH 1202 Geneva, Switzerland.

The Groups principal place of business is Chemin

des Mines 9, CH 1202 Geneva, Switzerland. Its registered shares are traded at the SIX Swiss Exchange, under the ticker symbol ADXN and

its American Depositary Shares (ADSs) on the Nasdaq Stock Market under the symbol "ADXN". ADSs represents shares that continue

to be admitted to trading on SIX Swiss Exchange.

These interim condensed consolidated financial

statements have been approved for issuance by the Board of Directors on November 21, 2024.

2. Basis of preparation

These interim condensed consolidated financial

statements for the nine-month period ended September 30, 2024, have been prepared under the historic cost convention and in accordance

with IAS 34 "Interim Financial Reporting" and are presented in a format consistent with the consolidated financial statements

under IAS 1 "Presentation of Financial Statements". However, they do not include all of the notes that would be required

in a complete set of financial statements. Thus, this interim financial report should be read in conjunction with the consolidated financial

statements for the year ended December 31, 2023.

Interim financial results are not necessarily

indicative of results anticipated for the full year. The preparation of these unaudited interim condensed consolidated financial statements

made in accordance with IAS 34 requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities

and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and

expenses during the reporting period. Although these estimates are based on management's best knowledge of current events and actions,

actual results ultimately may differ from those estimates. The areas involving a higher degree of judgment which are significant to the

interim condensed consolidated financial statements are disclosed in note 4 to the consolidated financial statements for the year ended

A number of new or amended standards and interpretations

became applicable for financial reporting periods beginning on or after January 1, 2024. Of the latter, the Group noted the publication

of IFRS S1 (General requirement for disclosure of sustainability-related financial information) and IFRS S2 (climate - related

Disclosures). The Group concluded that those new IFRS standards were not relevant as the Group did not opt for the publication of a sustainability

report in accordance with Six Swiss Exchange listing rules.